Revvity Inc Stock Price, News & Analysis

Revvity (NYSE: RVTY) has announced its participation in the 43rd annual J.P. Morgan Healthcare Conference scheduled for January 13, 2025, at 8:15 a.m. PT in San Francisco. President and CEO Prahlad Singh will present an update on the company's strategic priorities and overall direction. The presentation will be accessible through a live audio webcast, with a replay available on the Revvity Investor Relations website for a minimum of 30 days following the event.

Revvity (NYSE: RVTY) announced an expanded collaboration with Genomics England to advance genomic initiatives across the UK. The partnership focuses on the Generation Study, a research program aiming to screen up to 100,000 newborns for 200 rare genetic conditions in England. Through its Omics laboratory in Manchester, Revvity will extract DNA from cord blood samples using the chemagic 360™ instrument. The collaboration aims to advance early detection of genetic conditions in newborns while also supporting the development of genomics talent across the UK region.

Revvity (NYSE: RVTY) has announced its participation in the 7th Annual Evercore ISI HealthCONx Conference scheduled for December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL. President and CEO Prahlad Singh will present an update on the company and its strategic priorities. The presentation will be accessible through a live audio webcast on the company's website's Events section, with a replay available on the Revvity Investor Relations website for at least 30 days following the event.

Scale Biosciences and Revvity's BioLegend (NYSE: RVTY) have launched the TotalSeq Phenocyte solution, a groundbreaking single-cell protein profiling technology. This innovation combines Scale Bio's Quantum Barcoding technology with BioLegend's TotalSeq antibody conjugates to enable more efficient identification and characterization of rare cell subtypes in immunology and oncology research.

The solution offers advantages over traditional methods like mass cytometry and flow cytometry by eliminating complex panel optimization and sophisticated instrumentation requirements, making it more accessible and scalable. It builds upon BioLegend's TotalSeq-A antibody panels and supports biomarker discovery without requiring dedicated instrumentation.

Revvity (NYSE: RVTY) has announced its upcoming Investor Day scheduled for November 21, 2024, at 9:00 a.m. PT. The company revealed strategic changes to its operating model, effective fiscal year 2025, including the integration of its Applied Genomics business into a new Life Sciences Solutions division.

The reorganization will result in two main reporting segments: Life Sciences (comprising Life Sciences Solutions and Software) and Diagnostics (including Immunodiagnostics and Reproductive Health). This restructuring aims to enhance operational efficiency, create synergies, and improve customer service delivery.

Revvity reported strong Q3 2024 financial results with revenue reaching $684 million, representing 2% reported and organic growth. GAAP EPS was $0.77, while adjusted EPS from continuing operations reached $1.28. The company's Diagnostics segment showed 6% growth with $383 million revenue, while Life Sciences recorded $301 million, a 2% decrease. Operating margins improved, with GAAP operating profit margin at 14.3% and adjusted operating profit margin at 28.3%. The company raised its full-year 2024 adjusted EPS guidance to $4.83-$4.87 and announced a new $1 billion share repurchase program.

Revvity (NYSE: RVTY) announced that its Board of Directors has declared a quarterly dividend of $0.07 per share of common stock. The dividend will be paid on February 7, 2025, to shareholders of record as of the close of business on January 17, 2025.

Revvity, Inc. (NYSE: RVTY) has launched Revvity Transcribe AI, an innovative optical character recognition (OCR) service that converts handwritten text on test request forms into digital format. This solution aims to streamline workflows and reduce manual data entry tasks in clinical laboratories. Key features include:

• 40% improvement in overall data entry workflow speed, including data validation
• Especially valuable for newborn screening (NBS) laboratories
• Compatible with Revvity's EVOYA™ platform for NBS software
• Secure data processing with ISO27001 compliance

The service allows laboratory personnel to focus on other essential tasks by automating the manually intensive process of transcribing handwritten information. Revvity Transcribe AI will be introduced at the 2024 APHL Newborn Screening Symposium in Omaha, Nebraska.

Revvity, Inc. (NYSE: RVTY) has released its annual Impact Report, showcasing the company's sustainability, social, and governance initiatives. Key highlights include:

• A 7% reduction in Scope 1 and 2 emissions in 2023
• Implementation of a sustainability due diligence program for suppliers
• 75% employee satisfaction with 85% participation in a survey
• Maintained 40% female representation in leadership positions
• Expanded gender pay gap analysis
• Introduction of new corporate policies on ethical AI, sustainable procurement, and cyber risk management
• Creation of Revvity Access STEM Scholarships

CEO Prahlad Singh emphasized the company's commitment to creating a healthier, cleaner, and more inclusive world through innovative solutions and sustainability initiatives.